Reported positive data updates from its ongoing Phase 2a trial of lead program IMM-1-104, including encouraging responses in combination with chemotherapy in first-line pancreatic cancer ...

Immuneering appoints Dr. Igor Matushansky as Chief Medical Officer to enhance clinical development of IMM-1-104 for pancreatic cancer. Immuneering Corporation announced the appointment of Dr. Igor ...

Immuneering Corporation (NASDAQ:IMRX) on Tuesday announced plans to add three new combination arms for its Phase 2a program for lead asset IMM-1-104 following favorable data against pancreatic cancer.

“The Phase 2a data we shared in January demonstrates the potential of IMM-1-104 to provide first line pancreatic cancer patients with a new option that is more effective and better tolerated ...

The trial aims to explore the dual-targeting potential of IMM-1-104 in conjunction with immuno-oncology agents such as PD-1 inhibitors. This potential was supported by preclinical data presented ...

“We were delighted to report updates from our ongoing Phase 2a trial of IMM-1-104 in January 2025 demonstrating excellent response rates for IMM-1-104 in combination with chemotherapy in first ...

Reported positive data updates from its ongoing Phase 2a trial of lead program IMM-1-104, including encouraging responses in combination with chemotherapy in first-line pancreatic cancer - - Announced ...